US5288723027
© Globe Newswire
23.01.2026
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
News Preview
THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.01.2026
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
News Preview
– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – – No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo –...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2026
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
News Preview
-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies-...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
07.01.2026
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 12:00 p.m. PT (3:00 p.m. ET) in San Francisco....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Globe Newswire
10.12.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
News Preview
Lexicon Pharmaceuticals announces publication of preclinical data in the Journal of the Endocrine Society....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
LXRX
LISTED
NASDAQ
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
News Preview
THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025,...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
News Preview
THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET and at the 8th Annual Evercore Healthcare Conference on Thursday, December...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2025
LXRX
LISTED
NASDAQ
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
News Preview
Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
News Preview
Lexicon Pharmaceuticals reported third quarter 2025 financial results and provided an update on key corporate milestones and accomplishments....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
News Preview
THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss th...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
News Preview
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
LXRX
LISTED
NASDAQ
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
News Preview
Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
11.09.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
News Preview
Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP)...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
News Preview
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
News Preview
THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
News Preview
THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on Wednesday, September 3 at 1:45 p.m. ET and at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, Sept...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
News Preview
THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss th...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2025
LXRX
LISTED
NASDAQ
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
News Preview
Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment for people suffering from DPNP Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment for people suffering from DPNP...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.03.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
News Preview
THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and full year 2024 financial results on Thursday, March 6, 2025 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that da...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.03.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
News Preview
Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025 Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.01.2025
LXRX
LISTED
NASDAQ
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
News Preview
Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.01.2025
LXRX
LISTED
NASDAQ
Lexicon Appoints Scott Coiante as Chief Financial Officer
News Preview
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.12.2024
LXRX
LISTED
NASDAQ
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
News Preview
Confirms Previously Disclosed and Anticipated FDA Decision Confirms Previously Disclosed and Anticipated FDA Decision...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2024
LXRX
LISTED
NASDAQ
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
News Preview
Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2024
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Participate in December Investor Conferences
News Preview
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive officer and director, will present at two upcoming investor conferences in December....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2024
LXRX
LISTED
NASDAQ
Lexicon Appoints Ivan H. Cheung to Board of Directors
News Preview
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors....
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2024
LXRX
LISTED
NASDAQ
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
News Preview
PDUFA target action date set for December 20, 2024 PDUFA target action date set for December 20, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2024
LXRX
LISTED
NASDAQ
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
News Preview
Post hoc analysis evaluated sotagliflozin in patients with diabetic kidney disease (DKD) Post hoc analysis evaluated sotagliflozin in patients with diabetic kidney disease (DKD)...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2024
LXRX
LISTED
NASDAQ
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
News Preview
-Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.09.2024
LXRX
LISTED
NASDAQ
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
News Preview
Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
News Preview
THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024. A search for a new chief financial officer is ongoing....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2024
LXRX
LISTED
NASDAQ
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
News Preview
Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin ...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.08.2024
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
News Preview
Advisory Committee Meeting Scheduled for October 31, 2024; PDUFA Goal Date Remains December 20, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2024
LXRX
LISTED
NASDAQ
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
News Preview
THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 - 12, 2024 at the Ernest N. Morial Convention Center in New Orl...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2024
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
News Preview
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2024
LXRX
LISTED
NASDAQ
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
News Preview
Jeff Wade Named President and Chief Operating Officer Jeff Wade Named President and Chief Operating Officer...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.06.2024
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
News Preview
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.06.2024
LXRX
LISTED
NASDAQ
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
News Preview
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP)...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
LXRX
LISTED
NASDAQ
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
News Preview
New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.06.2024
LXRX
LISTED
NASDAQ
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
News Preview
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024 at the Orange County Convention Center in Orlando, Florida....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
